




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61M 16/04, 16/10, A61B 5/08</p>	<p>A1</p>	<p>(11) International Publication Number: WO 97/02065 (43) International Publication Date: 23 January 1997 (23.01.97)</p>
<p>(21) International Application Number: PCT/SE96/00912 (22) International Filing Date: 4 July 1996 (04.07.96) (30) Priority Data: 9502442-8 5 July 1995 (05.07.95) SE (71)(72) Applicants and Inventors: ALVING, Kjell [SE/SE]; Spetsvägen 40, S-757 57 Uppsala (SE). LUNDBERG, Jan, M. [SE/SE]; Helgevägen 10, S-182 64 Djursholm (SE). LUNDBERG, Jon [SE/SE]; St. Eriksgatan 116, S-113 31 Stockholm (SE). WEITZBERG, Eddie [SE/SE]; Starrängsringen 36, S-115 50 Stockholm (SE). (74) Agents: ONN, Thorsten et al.; AB Stockholms Patentbyrå, Zacco & Bruhn, P.O. Box 23101, S-104 35 Stockholm (SE).</p>		<p>(81) Designated States: AU, CA, JP, SE, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i></p>

(54) Title: VENTILATOR DEVICE



(57) Abstract

The present invention restores the normal low-dose flushing of the lower airways with air from the upper airways, containing nitric oxide (NO) and possible other biologically active agents by aspiration of air from the upper airways and introducing said air in the inspiratory airflow of a ventilator. The inventive apparatus and method are free from the risks associated with traditional administration of exogenous NO.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

VENTILATOR DEVICE**Field of the invention**

The present invention relates to the collection of naturally occurring gases from the upper airways in an intubated or tracheostomized mammal, said gases including biologically active agents, e.g. gaseous nitric oxide (NO) from endogenous sources; and
5 the introduction of said gases, including said agents, e.g. NO in the inspiratory airflow from a ventilator.

Description of the background of the invention

Healthy humans normally breathe mostly through the nose, whereby the upper airways and especially the nasal cavity serves to regulate the temperature and humidity of
10 the inhaled air. But the upper airways do not only function as an ingenious heat exchanger and humidifier; they are also thought to be the source of endogenous, biologically active agents, such as endogenous nitric oxide (NO).

Nitric oxide (NO) is synthesized from the amino acid arginine by specific enzymes (NO-synthase) present in many cell types in the human body. Endogenous NO is
15 thought to play a key role as an effector molecule with many biological effects including vasodilatation, neurotransmission and host defence. The biological effects of NO are mostly attributed to its rapid reaction with certain iron-containing enzymes resulting in either activation or inactivation of the enzyme. For example, NO produced in vascular endothelium diffuses to smooth muscle cells and binds to the heme moiety of soluble
20 guanylate cyclase resulting in activation of the enzyme, formation of cyclic GMP and subsequently vasodilatation. NO produced by e.g. activated macrophages, may also have bacteriostatic and antiviral properties, thereby contributing to unspecific host defence.

Inhalation of exogenous NO gas has been used to reduce pulmonary vascular resistance in subjects with pulmonary hypertension. NO acts as a dilator of the pulmonary
25 circulation when administered by the inhalation route. As soon as NO reaches the circulation it reacts with e.g. haemoglobin and is inactivated. Thus, NO may act selectively on pulmonary and bronchial circulation without affecting systemic circulation. Clinical trials are presently performed to explore the clinical outcome of exogenous NO inhalation in the treatment of certain pulmonary vascular disorders.

30 It is essential to handle exogenous NO with extreme caution, since high doses may be very dangerous, even lethal. NO reacts rapidly with oxygen to form NO₂. Higher doses of NO₂ may result in delayed haemorrhagic pulmonary edema. Furthermore, high concentrations of inhaled NO may result in methaemoglobinaemia due to competitive

interaction with oxygen binding to haemoglobin.

Due to the above mentioned dangers of exogenous NO, it is vital to most carefully monitor the amounts of NO and NO₂ in inhaled air of patients receiving inhalation NO therapy. This may be carried out by connecting a NO/NO₂ analyzer (e.g. an apparatus using chemiluminescence technique) for on-line registration of NO/NO₂ concentrations in the inspirational airflow leaving the ventilator and distributed to the patient. Additionally, due to the rapid reaction of NO with oxygen, compressed NO gas must be kept in gas bottles free from oxygen. The gas administered to the patient should also be led through NO₂ scavenging arrangements, such as containers with soda lime.

The guidelines concerning therapeutic use of NO, issued by the Swedish Medical Products Agency (Läkemedelsverkets riktlinjer för användning av kvävemonoxid på licens i samband med ventilatorbehandling, April 25, 1995) emphasize the risks associated with formation of NO₂. Acute toxic effects are known and possible mutagenic effects can not be ruled out. The guidelines specify that the concentration of NO₂ in the inspiratory flow must be guaranteed to be less than 2 ppm at all times. Strict monitoring requirements are laid out, including continuous monitoring of the oxygen concentration in the inspiratory gasflow; continuous percutaneous oximetry, arterial blood gas analyses including oxygen saturation; monitoring of central venous blood pressure; and determinations of blood methaemoglobin at least twice daily and for children under one year of age, at least four times daily.

In the prior art a blend of NO in N₂ is used with NO at concentrations of approximately 100 to 1000 ppm. Oxygen-free NO is mixed with air and thereby diluted to the desired final concentration immediately before administration to the patient. A flow controller should be used to achieve an appropriate blend of NO and air. All equipment should be regularly calibrated and a manual backup system should be available. To avoid risk to personnel working with NO inhalation therapy NO bottles should be kept in a well-ventilated room.

In all published reports of NO-inhalation therapy, an exogenous source has been used and the reports contain mentions of the safety precautions taken.

WO 92/10228 discloses an inhaler device for administering NO to a patient, said device comprising a vessel containing pressurized gas comprising at least 1 ppm NO; a housing defining a lumen, said vessel being attached to said housing to deliver said gas

into said lumen; and a mechanism for controllably releasing said gas from said vessel into said lumen; said lumen being configured to route said released gas into the respiratory system of a person, and said device weighing less than approximately 5 kg. In the description only exogenous sources of NO are mentioned and the NO is said to be
5 administered in concentrations ranging from 1 to 40 ppm and momentarily even increased to 80 - 180 ppm.

Further WO 91/14469 describes an apparatus and method for selective, separate or simultaneous collection and analysis of nasal and oral gases, respired by a patient, with optional simultaneous delivery to the patient of selected inhalant gases. The apparatus is
10 specifically constructed and arranged to avoid or minimize contact with the patients' mouth or other facial surfaces. This is obviously far from the applications concerned in the present invention, that is collecting endogenous gases, in particular NO and supplying the same gases to an intubated or tracheostomized patient through the inhalatory flow of a ventilator. WO 91/14469 mentions the collection and analysis of various exhaled gases
15 and, additionally the administration of oxygen or air, or a mixture of oxygen and air or of oxygen and water vapour and anaesthetic gases. No mention of administering an endogenous gas back to the patient can be found in the description or claims.

It is known that NO is endogenously produced in the upper airways of healthy subjects. NO is normally present in nasal air at concentrations ranging from 0,1 to 5 ppm.
20 The present inventors have found that the synthesis of NO in the upper airways is mostly carried out by a high producing "inducible like" NO synthase (NOS) situated in the epithelial cells of the paranasal sinuses. NO is probably also produced in the nasal cavity and in the nasopharynx. The present inventors have found that sinus derived air normally enters the nasal cavity through the ducts connecting the sinuses with the nose and is a
25 large contributor to NO found in nasally exhaled air. In contrast, NO excretion in the lower airways and the lungs seems to be very low since tracheostomized patients exhibit only low NO levels when exhaling through the tracheostomy. Furthermore the high producing "inducible like" NOS described in normal paranasal sinuses is not normally present in the lower airways of healthy subjects. NO produced in the upper airways not only
30 follows the airstream out with every exhalation but also flows down to the lower airways and lungs with every inhalation. Therefore a continuous low-dose NO flushing of the lower airways takes place normally in healthy subjects. However, patients with an endotracheal tube or tracheostomy are deprived of this self administration of NO since the

upper airways, where most of airway NO production takes place, are by-passed by the intubation manoeuvre.

It is contemplated that also other endogenous agents, for example other gases or other endogenous, systemic or locally active agents, are synthesized in the upper airways. 5 These agents can be any biologically active agent or agents, chosen from the group including hormones, enzymes, substrates, large molecular proteins, fractionated proteins, in the form of aerosols, droplets or gases. Patients with an endotracheal tube or tracheostomy are however deprived of the beneficial effects of these endogenous, biologically active agents. This can be especially significant in intubated or tracheostomized 10 children, who normally breath almost exclusively through the nose.

Summary of the invention

The present invention as set forth in the appending patent claims eliminates the previously described safety problems associated with the administration of NO, including the possible occupational health risks to personnel administering NO therapy. The present 15 invention restores the natural delivery of endogenous, biologically active agents, including NO to the lower airways occurring in healthy subjects. Additionally the apparatus according to the present invention, when integrated with or operated conjunctly with a ventilator, will reduce the negative side effects of artificial ventilation in intubated or tracheostomized patients. Therefore it is suitable for all intubated or tracheostomized 20 patients during ventilator therapy. The apparatus according to the present invention additionally provides for safe and convenient administration of NO without interfering with the normal functions and safety requirements of a ventilator. The apparatus and method according to the present invention will additionally restore the administration of any hitherto unknown, endogenous, biologically active agent or agents to the lower 25 airways.

Brief description of the drawings

In the following are presented drawings for better understanding of the invention, whereby these drawings are in no way intended to limit the scope of the invention as set forth in the appended claims. In the drawings

30 Figure 1a is a schematic view of an apparatus according to the invention, including a transverse section of the upper airways;

Figure 1b is a schematic frontal view, showing the sinuses;

Figure 2 is a schematic view of a preferred embodiment of the invention where

moist air is reintroduced in the nostrils; and

Figure 3 is a graph, showing the effects of intermittently applied sub ppm doses of NO on pulmonary vasculatory resistance and oxygen saturation in blood of ventilated patients.

5

Description of the preferred embodiments

In the following "upper airways" refers to the airways located above the vocal cords, including the paranasal sinuses, nasal cavity, nasopharynx, epipharynx, oropharynx, oral cavity and the hypopharynx. The term "nasal airways" refers to the airways extending from the nostrils to the nasopharynx. The term "endogenous NO" denotes nitric oxide produced within the body of a mammal, preferably a human. "Ventilator" denotes generally a machine that delivers air or an oxygen containing mixture of gases into the lungs of a patient who has insufficient breathing function, for example due to paralysis or sedation. The term "inspiratory airflow of a ventilator" is used to include the flow of gases through a ventilator, administered to a patient, extending from the source or sources of air and gas, e.g. containers of pressurized gases, to the lower end of a respiratory duct, cuffed or otherwise secured in the trachea of a patient.

According to the present invention air is collected from the upper airways in an intubated or tracheostomized mammal, preferably a human and said collected air is reintroduced to the inspiratory flow of a ventilator. Specifically said air contains endogenous, biologically active agents, such as NO from endogenous sources. Such endogenous sources of NO are preferably the upper airways extending to the larynx. Another source of endogenous NO, related to the airways through the oesophagus, is the gastrointestinal tract. It is also contemplated that air, aspirated from the upper airways, could be collected from a patient prior to an operation requiring intubation and artificial ventilation of said patient, whereby this previously collected air, including endogenous NO could be administered to the patient. The possibility of donation, i.e. the administration of sterile filtered NO-containing air drawn from the upper airways of a donor to a patient with temporary or permanent lack of upper airway production of NO, should not be dismissed.

Naturally said air containing NO and possibly other biologically active endogenous agents, is collected in such a way that renders a NO-containing gas flow, suitable for introduction in the inspiratory airflow of a ventilator. If necessary the gas flow should be subjected to further treatment, such as filtering and similar treatment, well understood by one skilled in the art of gas therapy. Care should of course be taken not to denaturate or

otherwise inactivate other beneficial, biologically active endogenous agents, possibly included in the gasflow.

The invention will now be described with reference to Fig. 1a, where air is collected from the upper airways, preferably from the nasal cavity (1) by introduction of occlusive catheters into one or both nostrils (2, only one shown). The catheters are further connected via flexible tubing to a pump for aspiration of air. The pump unit (3) can further contain a filter and necessary valves, including a pressure release valve or valves to avoid any possible harm to the patient. The flow rate of the pump is controlled by a control unit (7) and can be adjusted within an interval of 0.001 to 5 l/min to optionally suit the given conditions (e.g. NO concentration, physiology of the subject). The aspirated air is led to a ventilator (4) having an inlet (5) for receiving air or a mixture of gases, including oxygen and an outlet (6) for venting the exhaled air. The ventilator is only schematically depicted and can naturally be any conventional ventilator. The ventilator is further connected, via respiratory tubes (8) to an endotracheal tube (9) cuffed in the trachea of a patient. Additionally a front view is shown in Fig. 1b, showing the location of the maxillary (10) and frontal sinuses (11) and the airflow in the same, when air is aspirated by a pump unit (3).

The aspiration of air is done either continuously or in a pulsating way, preferably in a pulsating way, i.e. that the pulse is set to aspirate air at preset intervals, simulating the natural breathing rhythm. The control unit (7) is preferably connected to the ventilator (4) for synchronization of the aspiration with the breathing movement. The option of blowing air, preferably moist air, back out through the nasal airways would be particularly preferable, as it further mimicks the natural airflow in unhindered breathing. It is highly probable, that the flow of air in and out through the nasal airways supports not only the normal functions of the sinuses but also improves the general conditions in the nasal airways.

Optionally both nostrils are connected to catheters, whereby ambient air is blown into one nostril while air is being aspirated from the other to further simulate natural breathing. Optionally both nostrils are aspirated and replenished simultaneously. In connection with a ventilator, functioning autonomously or in a patient triggered mode, the aspiration/blowing in the nostrils is synchronized with the functions of the ventilator.

The aspiration of nasal air must be designed so as to achieve optimal amounts of beneficial, biologically active, endogenous agents, such as NO without causing damage to

the nasal mucosa. Drying up of the nasal mucosa should be avoided. For this purpose a moisturizing filter can be applied to the catheter leading air into the nostrils. Optionally a part of the airflow exhaled by the patient can be returned to the nostrils, thereby utilizing the naturally occurring moisture in the exhaled air (See Fig. 2). In this setting a CO₂ absorbing filter (Not shown in the figure) is preferably used to avoid accumulation of CO₂ in the circulating air. In Fig. 2 catheters (2) are arranged in both nostrils and part of the moist exhaled air is taken from the exhalatory limb (8) and led back to the upper airways through one nostril while air is aspirated from the other. Here the pump unit is replaced by two pump units (3A and 3B) both controlled by control unit 7, connected to the ventilator. The ventilator further has an intake (5) for receiving exogenous gases or air and an outlet (6) for venting exhaled air. The respiratory limb of the ventilator is connected to an endotracheal tube (9, shown as dashed lines) cuffed in the trachea of the patient. Using a simple three-way valve or similar connection (not shown) the aspiration / pumping can be alternated between the nostrils. The degree of desiccation can also be influenced by keeping the aspiratory flow rate as low as possible.

An embodiment of the invention, not shown in the appended drawings, aims at further mimicking the natural breathing pattern of a mammal, i.e. nasal breathing. In this embodiment air is aspirated from the nasopharynx through a catheter or catheters, introduced orally, running parallel to the endotracheal tube. Thereby air is aspirated inwards, through the nose, in a manner more similar to normal breathing. This embodiment further makes possible the blowing of air, preferably moist air, outwards through the nasal airways. This further mimicks the natural breathing pattern and associated airflows, aiding the normal functioning of the sinuses and the general balance in the nasal airways. A hypothesis, based on the geometry of the nasal airways and the sinuses, would be that gas is aspirated from the sinuses in the inhalation phase and, consequently, that the sinuses are replenished with air in the exhalation phase.

The NO concentration delivered to the inspiratory airflow of a ventilator should be such that the concentration in the air delivered to the patient is in the interval of 5 to 200 ppb (parts per billion) during continuous delivery. Alternatively the collected NO can be temporarily stored in a vessel, made of NO non-absorbing material, e.g. glass, steel or an appropriate plastic, conventionally used in the field of medicine, e.g. Teflon[®]. Preferably said vessel is a flexible, bellows-like vessel made of Teflon[®] or equivalent material. Using such a reservoir higher doses of NO can be released in the inspiratory airflow of an

ventilator at preset intervals. The mean concentration of NO delivered to the patient should preferably still be less than 1 ppm (part per million).

The aspirated air containing NO and possible other biologically active agents is introduced in the inspiratory airflow of a ventilator either continuously or collected in an intermediate reservoir and released intermittently, for example introduced with intervals of
5 a preset number of breaths.

Although the present invention primarily concerns collecting air from the upper airways, including biologically active agents, such as endogenous NO and supplying it to the inspiratory airflow of a ventilator connected to an intubated or tracheostomized
10 patient, it can naturally also be practised in connection with a ventilator connected to a laryngeal mask, applied on the patient. When a facial mask is used, in connection with a ventilator or a source of air or oxygen, the supply of endogenous NO is contemplated only when the patient has insufficient NO synthesis in the upper airways or is unable to breath through the nose. The extraction of endogenous NO from the upper airways is contempla-
15 ted also for patients being chronically tracheostomized and thus deprived of their natural NO.

Generally the administration of endogenous NO is contemplated for supply to the inspiratory airflow of a ventilator or similar device for restoring pulmonary function and improving non-specific host defence in the airways of all intubated or tracheostomized
20 patients. The present invention aims to supplement air from the upper airways to the lower airways, i.e. restore the circulation of air taking place during normal breathing. Therefore it is thought to be of use as a standard procedure in all intubated or tracheostomized patients irrespective of diagnosis.

The biological effects of NO extend beyond vasodilatation. Thus, NO has also
25 bacteriostatic and antiviral properties and has been shown to increase ciliary beat frequency in respiratory epithelium. All these properties of NO may be of importance in normal unspecific host-defence of the airways. Therefore, inhibition of normal airway NO synthesis may increase susceptibility to respiratory tract infections. That is what happens in intubated or tracheostomized subjects since the main supply of endogenous NO to the
30 lower airways is disconnected. Indeed, it is known that long-term ventilated patients have impaired mucociliary clearance and that they are almost obligatory colonized by bacteria in the trachea and the lower airways, often resulting in severe lower respiratory tract infections. Furthermore, children with Kartagener's syndrome (a triad consisting of

sinusitis, bronchiectasis and sinus inversus) lack NO excretion in the upper airways and these patients have severe problems with repeated airway infections including bronchitis and pneumonia. Children in general are an important patient group as the inventive method would help to avoid the previously described risks of administering exogenous NO
5 and simultaneously restore the natural nasal breathing pattern typical for children.

The present invention restores the normal low-dose flushing of the lower airways with air from the upper airways, containing NO and possible other biologically active agents. This leads to a reduction in pulmonary vascular resistance and improved oxygenation. Furthermore, endogenous NO may prevent airway infections caused by bacteria,
10 virus, fungi or other pathogens and may also improve mucociliary clearance.

Sinusitis is a common problem among long-term ventilated patients. Up to 70 % of these patients show non-pneumatized sinuses on X-ray. A common cause of sinusitis in general is thought to be a swelling of the mucosa surrounding the ostia, leading to impaired ventilation and drainage of the sinuses. The present invention may help to avoid
15 said poor ventilation of the sinuses by airflow applied to the nasal airways. This airflow may prevent swelling of the sinuses and improve ventilation of the sinuses by simulating the normal breathing cycle. Indeed, earlier studies have shown that the ventilation of the sinuses is improved by nasal breathing.

It is contemplated that the administration of endogenous NO increases the uptake
20 of pulmonary administered pharmaceuticals and simultaneously, that certain pharmaceuticals potentiate the effect of the endogenous NO. Consequently it is suggested by the present inventors that pharmaceutical agents are introduced in the flow of gases containing endogenous NO derived from the upper airways before introduction in the inspiratory airflow of a ventilator or similar device. Thus the apparatus for feeding nasal air,
25 including endogenous NO to the inspiratory airflow of a ventilator can be used as a convenient route for administration of pharmaceutical agents in the form of aerosols or fine powders, without interfering with the normal functions of the ventilator.

Examples

The present inventors investigated whether the restoring of the normal flushing of
30 the lower airways with gases collected from the upper airways, including the normal low-dose NO inhalation, would influence pulmonary vascular resistance (PVR) and arterial blood oxygenation in intubated patients.

In the experiments gases were collected from the upper airways of the patients by

aspiration (2 l/min) from one nostril and led into the inhalation limb (i.e. the inspiratory airflow) of a standard ventilator. 15 patients were studied. The NO concentration in inhaled air, after addition of the nasally derived air was in the interval of 5 to 45 ppb with the aspiration method used. In comparison less than 2 ppb NO was inhaled by the patients
5 when no nasally derived air was introduced. The results are presented in Fig. 3. The graphs show the effects of self-administration of nasal gases on pulmonary vascular resistance (PVR, filled circles) and arterial oxygenation (PaO_2 , empty circles) in an intubated subject. Air was aspirated in repeated 10 min periods, either from a nostril of a patient (bars) or from ambient air ($\text{NO} < 3$ ppb) and reintroduced into the inhalation limb
10 of a ventilator. Measurements of PVR and PaO_2 were made at the end of the 10 min periods.

In 70 % of the patients, an acute rise in arterial PaO_2 in the range of 8 to 25 %, was observed when adding nasal air to the inspired air. Furthermore, in five patients the pulmonary vascular resistance decreased by 15 ± 4 % during the same procedure. Similar
15 responses were observed when exogenous NO at the same concentration was added to the inspired air. The results indicate that endogenous NO and possibly other biologically active agents, produced in the upper airways, are involved in the basal regulation of PVR through continuous low-dose self inhalation. Mechanically ventilated patients are deprived from self inhalation of endogenous NO and other possible endogenous substances and
20 replacement of this loss may improve vital pulmonary functions.

An apparatus according to the present invention can preferably be included as a standard feature in ventilators. Likewise the method according to the present invention can be included as a standard procedure in the treatment not only of mechanically ventilated patients but also of any person with restricted inhalatory flow through the upper airways.

25 Although the invention has been described with regard to its preferred embodiments, which constitute the best mode presently known to the inventors, it should be understood that various changes and modifications as would be obvious to one having the ordinary skill in this art may be made without departing from the scope of the invention which is set forth in the claims appended hereto.

30 -----

Claims

1. An apparatus for collecting gases from the upper airways and supplying said gases to the inspiratory airflow of a ventilator or similar device connected to an intubated or tracheostomized patient.
- 5 2. Apparatus according to claim 1, characterized in that the gases are collected in a way, so as to contain endogenous, biologically active agents, including endogenous NO.
3. Apparatus according to claim 2, characterized in that the gases including endogenous NO are collected by means of connecting the nasal airways of the patient to an aspirating device and leading the collected gases including NO to the inspiratory airflow of
10 a ventilator.
4. Apparatus according to claim 3, characterized in that the gases including endogenous NO are collected by means of connecting at least one nostril of the patient to an aspirating device and leading the collected gases including NO to the inspiratory airflow of a ventilator.
- 15 5. Apparatus according to any one of claims 3 to 4, characterized in that the aspirating device is operated continuously.
6. Apparatus according to any one of claims 3 to 4, characterized in that the aspirating device is operated intermittently.
7. Apparatus according to any one of claims 3 to 6, characterized in that the
20 gases including NO are collected in a reservoir and released periodically to the inspiratory airflow of a ventilator or similar device.
8. Apparatus according to any one of the previous claims, characterized in that moist air is introduced in the nostrils to prevent desiccation of the nasal mucosa.
9. Apparatus according to any one of the previous claims, characterized in that
25 the aspirating device is synchronized with the breathing rhythm of the patient.
10. Apparatus according to any one of the previous claims, characterized in that it comprises means for blowing air out through the nasal airways in a manner mimicking normal exhalation.
11. A method for treating an intubated or tracheostomized patient with gases
30 collected from the upper airways of a patient, whereby said gases are introduced to the inspiratory airflow of an ventilator.
12. Method according to claim 11, characterized in that the gases contain biologically active agents, preferably endogenous NO.

13. Method according to claim 12, characterized in that the gases including NO are collected by means of connecting the nasal airways of a patient to an aspirating device.

14. Method according to claim 13, characterized in that the gases including NO
5 are collected by means of connecting at least one nostril of a patient to an aspirating device.

15. Method according to any one of claims 13 to 14, characterized in that the aspirating device is operated continuously.

16. Method according to any one of claims 13 to 14, characterized in that the
10 aspirating device is operated intermittently.

17. Method according to any of claims 13 to 16, characterized in that the gases including NO are collected in a reservoir and released periodically to the inspiratory airflow of a ventilator or similar device.

18. Method according to any of the previous claims, characterized in that
15 moist air is introduced in the nostrils to prevent desiccation of the nasal mucosa.

19. Method according to any one of the previous claims, characterized in that the aspiration and reintroduction of air in the nasal cavity is synchronized with the breathing rhythm of the patient.

20. Method according to any one of the previous claims, characterized in that air
20 is blown out through the nasal airways in a manner mimicking normal exhalation.

21. Method according to any one of the previous claims, characterized in that pharmaceutical agents are administered in the flow of air, aspirated from the upper airways and introduced in the inspiratory airflow of a ventilator.




Fig. 1a




Fig. 1b




Fig. 2

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 96/00912

A. CLASSIFICATION OF SUBJECT MATTER		
IPC6: A61M 16/04, A61M 16/10, A61B 5/08 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC6: A61M, A61B		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
WPI, EPODOC		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9114469 A1 (DERRICK, S.J.), 3 October 1991 (03.10.91) --	1-10
A	WO 9119526 A1 (SIEMENS-ELEMA AB), 26 December 1991 (26.12.91) --	1-10
A	WO 9210228 A1 (THE GENERAL HOSPITAL CORPORATION), 25 June 1992 (25.06.92) -- -----	1-10
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
28 October 1996		30.10.96
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer Eva Johansson Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 96/00912

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 11-21
because they relate to subject matter not required to be searched by this Authority, namely:

See PCT Rule 39 1.(iv).: Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

01/10/96

International application No.

PCT/SE 96/00912

Patent document cited in search report	Publication date	Patent family member(s)	Publication date		
WO-A1- 9114469	03/10/91	AU-B- 643276	11/11/93		
		AU-A- 7670791	21/10/91		
		CA-A- 2078447	28/09/91		
		EP-A- 0673265	27/09/95		
		US-A- 4976260	11/12/90		
		US-A- 5046491	10/09/91		
		-----	-----	-----	-----
WO-A1- 9119526	26/12/91	EP-A,B- 0592413	20/04/94		
		JP-T- 5509010	16/12/93		
		SE-C- 500550	11/07/94		
		SE-A- 9002161	19/12/91		
		US-A- 5400778	28/03/95		
		-----	-----	-----	-----
WO-A1- 9210228	25/06/92	AU-B- 657726	23/03/95		
		AU-A- 9149891	08/07/92		
		CA-A- 2097823	06/06/92		
		DE-T- 560928	22/09/94		
		EP-A- 0560928	22/09/93		
		ES-T- 2082732	01/04/96		
		JP-T- 6504778	02/06/94		
		US-A- 5485827	23/01/96		
		US-A- 5536241	16/07/96		
		-----	-----	-----	-----